amlodipine has been researched along with quinidine in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Caron, G; Ermondi, G; Lorenti, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Brincat, JP; Broccatelli, F; Carosati, E; Cruciani, G; Frosini, M; Kaatz, GW; Neri, A; Sabatini, S | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, Y; Qi, L; Wei, X; Yang, G | 1 |
1 review(s) available for amlodipine and quinidine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
16 other study(ies) available for amlodipine and quinidine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Contribution of ionization and lipophilicity to drug binding to albumin: a preliminary step toward biodistribution prediction.
Topics: Chromatography, Affinity; Hydrogen-Ion Concentration; Ions; Models, Molecular; Molecular Conformation; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Serum Albumin, Bovine; Ultracentrifugation | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Ligand Promiscuity between the Efflux Pumps Human P-Glycoprotein and S. aureus NorA.
Topics: | 2012 |
Determination of nicardipine and amlodipine in human plasma using on-line solid-phase extraction with a monolithic weak cation-exchange column.
Topics: Amlodipine; Calibration; Cations; Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Humans; Hydrogen-Ion Concentration; Molecular Structure; Nicardipine; Online Systems; Quinidine; Serum Albumin; Solid Phase Extraction | 2009 |